Cart
sales@molnova.com
1-Phenyloctane
CAS No. 2189-60-8
1-Phenyloctane( —— )
Catalog No. M28960 CAS No. 2189-60-8
1-Phenyloctane enhances the liquid-phase exfoliation of graphene in organic solvents.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 32 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 43 | In Stock |
|
| 25MG | 73 | In Stock |
|
| 50MG | 107 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | 241 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name1-Phenyloctane
-
NoteResearch use only, not for human use.
-
Brief Description1-Phenyloctane enhances the liquid-phase exfoliation of graphene in organic solvents.
-
Description1-Phenyloctane enhances the liquid-phase exfoliation of graphene in organic solvents.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2189-60-8
-
Formula Weight190.33
-
Molecular FormulaC14H22
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCCCCCc1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhou et al. The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis. Journal of Clinical Oncology 2016 34:15_suppl, e20502-e20502
molnova catalog
related products
-
Isolindleyin
Isolindleyin is a natural product.
-
BMS986260
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?
-
BCPA
BCPA is a non-cytotoxic Pin1 modulator.BCPA modulates osteoclast activation and attenuates the reduction of Pin1 protein, thereby inhibiting RANKL-induced receptor activators of osteoclastogenesis.BCPA is used in the study of osteoporosis.
